Sui-Yuan Chang to HIV Infections
This is a "connection" page, showing publications Sui-Yuan Chang has written about HIV Infections.
Connection Strength
0.291
-
Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19. J Formos Med Assoc. 2021 Dec; 120(12):2186-2190.
Score: 0.036
-
Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Int J Antimicrob Agents. 2019 Jul; 54(1):35-42.
Score: 0.031
-
Dolutegravir-rilpivirine coformulation. Curr Opin HIV AIDS. 2018 07; 13(4):320-325.
Score: 0.030
-
Neutralizing antiinterferon-? autoantibodies causing disseminated Mycobacterium avium complex infection in an HIV-infected patient on successful combination antiretroviral therapy. AIDS. 2017 11 28; 31(18):2557-2559.
Score: 0.028
-
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy. Sci Rep. 2017 11 23; 7(1):16187.
Score: 0.028
-
Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. BMJ Open. 2017 Oct 16; 7(10):e015142.
Score: 0.028
-
Long-term Durability of Responses to 2 or 3 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Adults on Antiretroviral Therapy. J Infect Dis. 2017 02 15; 215(4):606-613.
Score: 0.027
-
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One. 2016; 11(12):e0169228.
Score: 0.027
-
Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor. J Infect Chemother. 2014 Aug; 20(8):465-70.
Score: 0.022
-
Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol. 2012 Mar; 50(3):781-7.
Score: 0.019
-
Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007 Nov 01; 45(9):1221-9.
Score: 0.014